Rubella virus vaccine

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
Rubella virus vaccine
Accession Number
DB10317
Description

Rubella virus vaccine is a live attenuated virus vaccine for active immunization against rubella (German measles) that is subcutaneously administered. It is prepared from RA 27/3 strain of live attenuated rubella virus. Rubella is a common childhood disease, caused by rubella virus (togavirus).

Type
Biotech
Groups
Approved, Investigational
Biologic Classification
Vaccines
Attenuated
Synonyms
  • Rubella virus (vaccine strain ra27/3) live antigen
  • Rubella virus live antigen, A
  • Rubella virus strain wistar ra 27/3 live (attenuated) antigen
  • Rubella virus strain wistar ra 27/3 live antigen
  • Rubella virus vaccine live (wistar ra 27-3 strain)
  • Rubella virus vaccine,live
  • Rubella, live attenuated
  • Rubivirus rubella virus wistar ra 27/3 whole

Pharmacology

Indication
Not Available
Associated Conditions
Contraindications & Blackbox Warnings
Learn about our commercial Contraindications & Blackbox Warnings data.
Learn More
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half-life
Not Available
Clearance
Not Available
Adverse Effects
Learn about our commercial Adverse Effects data.
Learn More
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
AbacavirThe therapeutic efficacy of Rubella virus vaccine can be decreased when used in combination with Abacavir.
AbataceptThe risk or severity of infection can be increased when Rubella virus vaccine is combined with Abatacept.
AcyclovirThe therapeutic efficacy of Rubella virus vaccine can be decreased when used in combination with Acyclovir.
AdalimumabThe risk or severity of infection can be increased when Rubella virus vaccine is combined with Adalimumab.
Adefovir dipivoxilThe therapeutic efficacy of Rubella virus vaccine can be decreased when used in combination with Adefovir dipivoxil.
AldesleukinThe risk or severity of infection can be increased when Rubella virus vaccine is combined with Aldesleukin.
AlefaceptThe risk or severity of infection can be increased when Rubella virus vaccine is combined with Alefacept.
AlemtuzumabThe risk or severity of infection can be increased when Rubella virus vaccine is combined with Alemtuzumab.
AltretamineThe risk or severity of infection can be increased when Rubella virus vaccine is combined with Altretamine.
AmantadineThe therapeutic efficacy of Rubella virus vaccine can be decreased when used in combination with Amantadine.
Additional Data Available
  • Extended Description
    Extended Description

    Extended description of the mechanism of action and particular properties of each drug interaction.

    Learn more
  • Severity
    Severity

    A severity rating for each drug interaction, from minor to major.

    Learn more
  • Evidence Level
    Evidence Level

    A rating for the strength of the evidence supporting each drug interaction.

    Learn more
  • Action
    Action

    An effect category for each drug interaction. Know how this interaction affects the subject drug.

    Learn more
Food Interactions
Not Available

Products

International/Other Brands
Meruvax II
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing EndRegionImage
M-M-R IIRubella virus vaccine (1000 TCID50/0.5mL) + Measles virus vaccine live attenuated (1000 TCID50/0.5mL) + Mumps virus strain B level jeryl lynn live antigen (12500 TCID50/0.5mL)Powder, for solutionSubcutaneousMerck Ltd.1979-12-31Not applicableCanada flag
M-M-R IIRubella virus vaccine (1000 [TCID_50]/0.5mL) + Measles virus vaccine live attenuated (1000 [TCID_50]/0.5mL) + Mumps virus strain B level jeryl lynn live antigen (12500 [TCID_50]/0.5mL)Injection, powder, lyophilized, for suspensionSubcutaneousA-S Medication Solutions1971-04-21Not applicableUS flag
M-M-R IIRubella virus vaccine (1000 [TCID_50]/0.5mL) + Measles virus vaccine live attenuated (1000 [TCID_50]/0.5mL) + Mumps virus strain B level jeryl lynn live antigen (12500 [TCID_50]/0.5mL)Injection, powder, lyophilized, for suspensionSubcutaneousPhysicians Total Care, Inc.1996-08-072012-06-30US flag
M-M-R IIRubella virus vaccine (1000 [TCID_50]/0.5mL) + Measles virus vaccine live attenuated (1000 [TCID_50]/0.5mL) + Mumps virus strain B level jeryl lynn live antigen (12500 [TCID_50]/0.5mL)Injection, powder, lyophilized, for suspensionSubcutaneousMerck Sharp & Dohme Corp.1971-04-21Not applicableUS flag
PriorixRubella virus vaccine (103.0 CCID50/0.5mL) + Measles virus vaccine live attenuated (103.0 CCID50/0.5mL) + Mumps virus strain B level jeryl lynn live antigen (103.7 CCID50/0.5mL)Kit; Powder, for solutionIntramuscular; SubcutaneousGlaxosmithkline Inc1998-12-04Not applicableCanada flag
ProQuadRubella virus vaccine (1000 [TCID_50]/0.5mL) + Measles virus vaccine live attenuated (1000 [TCID_50]/0.5mL) + Mumps virus strain B level jeryl lynn live antigen (20000 [TCID_50]/0.5mL) + Varicella Zoster Vaccine (Live/attenuated) (9772 [PFU]/0.5mL)Injection, powder, lyophilized, for suspensionSubcutaneousMerck Sharp & Dohme Corp.2015-07-01Not applicableUS flag
ProQuadRubella virus vaccine (1000 [TCID_50]/0.5mL) + Measles virus vaccine live attenuated (1000 [TCID_50]/0.5mL) + Mumps virus strain B level jeryl lynn live antigen (20000 [TCID_50]/0.5mL) + Varicella Zoster Vaccine (Live/attenuated) (9772 [PFU]/0.5mL)Injection, powder, lyophilized, for suspensionSubcutaneousMerck Sharp & Dohme Limited2005-09-062018-08-31US flag
ProQuadRubella virus vaccine (3 log10 tcid50/0.5mL) + Measles virus vaccine live attenuated (3 log10 tcid50/0.5mL) + Mumps virus strain B level jeryl lynn live antigen (4.3 log10 tcid50/0.5mL) + Varicella Zoster Vaccine (Live/attenuated) (3.99 log10 tcid50/0.5mL)Powder, for solutionSubcutaneousMerck Ltd.2014-05-09Not applicableCanada flag

Categories

ATC Codes
J07BJ01 — Rubella, live attenuated
Drug Categories
Classification
Not classified

Chemical Identifiers

UNII
52202H034Z
CAS number
Not Available

References

General References
  1. TITCK Product Information: R-VAC (rubella vaccine, live, attenuated) for subcutaneous injection [Link]
PubChem Substance
347910496
RxNav
9486

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
4CompletedPreventionBCG Infection / Immune Response / Reaction - Vaccine1
4CompletedPreventionChickenpox / Hepatitis A / Mumps / Rubella / Rubeola1
4CompletedPreventionEncephalitis, Japanese B / Mumps / Rubella / Rubeola1
4CompletedPreventionHepatitis A Virus1
4CompletedPreventionMeasles Antibody Seroconversion / Rotavirus Geometric Mean Titer (GMT) / Rotavirus Immunoglobulin A (IgA) Seropositivity / Rubella Antibody Seroconversion1
4CompletedPreventionMumps / Rubella / Rubeola2
3Active Not RecruitingPreventionMalaria Vaccines / Plasmodium Infections1
3Active Not RecruitingTreatmentInfections, Pneumococcal1
3CompletedPreventionAcellular Pertussis / Diphtheria / Poliomyelitis / Tetanus1
3CompletedPreventionAcellular Pertussis / Diphtheria / Tetanus1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
FormRouteStrength
Injection, powder, lyophilized, for suspensionSubcutaneous
Injection, powder, for suspensionIntramuscular; Subcutaneous1000 CCID50/0.5mL
Injection, powder, lyophilized, for solutionIntramuscular; Subcutaneous1000 TCID
Injection, powder, for solutionIntramuscular; Subcutaneous103 CCID50/0.5mL
Injection, powder, for solutionSubcutaneous103 CCID50/0.5mL
Kit; powder, for solutionIntramuscular; Subcutaneous
Injection, powder, lyophilized, for solutionIntramuscular; Subcutaneous10 CCID
Injection, powder, for solutionSubcutaneous10 CCID
Injection, powder, lyophilized, for solutionSubcutaneous10 CCID
Injection, powder, for suspensionIntramuscular; Subcutaneous1000 [TCID_50]/0.5mL
Injection, powder, lyophilized, for suspensionIntramuscular; Subcutaneous1000 [TCID_50]/0.5mL
Powder, for solutionSubcutaneous
Injection, powder, lyophilized, for suspensionIntramuscular; Subcutaneous3 log10/0.5ml
InjectionSubcutaneous0.5 ml
InjectionSubcutaneous1000 CCID50/0.5mL
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available

Drug created on December 01, 2015 13:03 / Updated on September 03, 2020 14:54

Logo pink
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
Logo pink
Stay in the know!
As part of our commitment to providing the most up-to-date drug information, we will be releasing #DrugBankUpdates with our newly added curated drug pages.
#DrugBankUpdates